Literature DB >> 26088823

THERAPY OF ENDOCRINE DISEASE: Central neck dissection: a step forward in the treatment of papillary thyroid cancer.

Antonio Sitges-Serra1, Leyre Lorente2, Germán Mateu2, Juan J Sancho2.   

Abstract

Since its introduction in the '70s and '80s, CND for papillary cancer is here to stay. Compartment VI should always be explored during surgery for papillary thyroid carcinoma (PTC) for obvious lymph node metastases. These can be easily spotted by an experienced surgeon or, eventually, by frozen section. No doubt, obvious nodal disease in the Delphian, paratracheal and subithsmic areas should be dissected in a comprehensive manner (therapeutic central neck dissection), avoiding the selective removal of suspicious nodes. Available evidence for routine prophylactic CND is not completely satisfactory. Our group's opinion, however, is that it reduces or even eliminates the need for repeat surgery in the central neck, better defines the extent (and stage) of the disease and provides a further argument against routine radioiodine ablation. Thus, PTC is becoming more and more a surgical disease that can be cured by optimized surgery alone in the majority of cases. Prophylactic CND, however, involves a higher risk for the parathyroid function and should be skilfully performed, preferably only on the same side as the primary tumour and preserving the cervical portion of the thymus.
© 2015 European Society of Endocrinology.

Entities:  

Mesh:

Year:  2015        PMID: 26088823     DOI: 10.1530/EJE-15-0481

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  5 in total

1.  European Thyroid Association Guidelines regarding Thyroid Nodule Molecular Fine-Needle Aspiration Cytology Diagnostics.

Authors:  Ralf Paschke; Silvia Cantara; Anna Crescenzi; Barbara Jarzab; Thomas J Musholt; Manuel Sobrinho Simoes
Journal:  Eur Thyroid J       Date:  2017-05-19

2.  Role of prophylactic central neck dissection in clinically node-negative differentiated thyroid cancer: assessment of the risk of regional recurrence.

Authors:  Pietro Giorgio Calò; Celestino Pio Lombardi; Francesco Podda; Luca Sessa; Luigi Santini; Giovanni Conzo
Journal:  Updates Surg       Date:  2017-04-13

3.  High-Dose RAI Therapy Justified by Pathological N1a Disease Revealed by Prophylactic Central Neck Dissection for cN0 Papillary Thyroid Cancer Patients: Is it Superior to Low-Dose RAI Therapy?

Authors:  Lan Wei; Lin Bai; Lina Zhao; Tianyu Yu; Qingjie Ma; Bin Ji
Journal:  World J Surg       Date:  2019-05       Impact factor: 3.352

4.  The Relationship of Clinicopathological Factors of the Tumor with Preoperative TSH Level in Papillary Thyroid Cancers.

Authors:  Evren Besler; Bulent Citgez; Nurcihan Aygun; Mustafa Fevzi Celayir; Müveddet Banu Yılmaz Ozguven; Mehmet Mihmanli; Sitki Gurkan Yetkin; Mehmet Uludag
Journal:  Eurasian J Med       Date:  2018-12-03

5.  Parathyroid autotransplantation at a novel site for better evaluation of the grafted gland function: study protocol for a prospective, randomized controlled trial.

Authors:  Qiuxia Cui; Deguang Kong; Zhihua Li; Kun Wang; Dan Zhang; Jianing Tang; Xing Liao; Qianqian Yuan; Yan Gong; Gaosong Wu
Journal:  Trials       Date:  2019-01-31       Impact factor: 2.279

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.